RBCC Partner n3D’s Latest Article Shows Magnetic Bioprinting’s Versatility And Promise

HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB: RBCC) partner n3D has gotten a key article published on a recognized medical technology company’s website, giving n3D and its considerable bioprinting expertise greater marketplace recognition and valuable exposure.

“n3D has made great strides in magnetic bioprinting and this is the only commercially viable 3D bioprinting process on the market. We believe this revolutionary technology will truly change medicine and we’re proud to have stood beside them through this development process.”

Promega, a life sciences company offering genomics, cellular analysis, drug discovery and genetic identity products and solutions, issued n3D’s paper, entitled, Luminescent Viability Assays in Magnetically Bioprinting 3D Cultures on its PubHub page, which offers ground-breaking articles on new technologies.

n3D’s publication demonstrates “a magnetic 3D bioprinting method for rapidly and reproducibly printing three-dimensional spheroids in high-throughput formats.” The paper proceeds to show how these spheroids can be successfully used in critical cell viability tests utilizing a number of specific products.

“The paper shows magnetic bioprinting’s tremendous utility and value in the life sciences field,” Souza said. “It is particularly useful in compound screening, as we discussed in the article. We continue to make rapid and substantial advancements using this cutting-edge technology that will soon lead to new drugs and treatments to many diseases. n3D’s bioprinting technologies have a distinct edge as they offer researchers simplicity of use when working with delicate tissues and cells. Magnetic bioprinting has strong research and commercial applications and we predict great market potential ahead.”

RBCC CEO Kimberly Palmer added, “n3D has made great strides in magnetic bioprinting and this is the only commercially viable 3D bioprinting process on the market. We believe this revolutionary technology will truly change medicine and we’re proud to have stood beside them through this development process.”

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.